NCT06039371View on ClinicalTrials.gov

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

May 21, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

December 31, 2027

Conditions
Castration-Resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaStage IVB Prostate Cancer AJCC v8
Interventions
PROCEDURE

Biopsy Procedure

Undergo a biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

DRUG

Carboplatin

Given IV

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Etoposide

Given PO

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DRUG

Testosterone Cypionate

Given IM

OTHER

Radioconjugate

Given LuPSMA IV

PROCEDURE

Dual X-ray Absorptiometry

Undergo DEXA

OTHER

Gallium Ga 68-PSMA-617

Given gallium 68Ga-PSMA-617

PROCEDURE

Positron Emission Tomography

Undergo 68Ga-PSMA PET

PROCEDURE

Single Photon Emission Computed Tomography

Undergo SPECT/CT

Trial Locations (1)

98109

RECRUITING

Fred Hutch/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER